{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:26:59Z","timestamp":1790000819851,"version":"4.0.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0012351","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000}}],"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-040110"],"award-info":[{"award-number":["INV-040110"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-040110"],"award-info":[{"award-number":["INV-040110"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Moxidectin is approved by the US Food and Drug Administration (US FDA) for the treatment of onchocerciasis (river-blindness) due to <jats:italic>Onchocerca volvulus<\/jats:italic> in patients aged 12 years and older. In onchocerciasis-endemic areas, mass drug administration (MDA) programs with ivermectin, with or without vector control, aim to control the disease, reduce morbidity, interrupt transmission, and more recently, achieve elimination. Moxidectin has the potential to be used in MDA programs. In countries where onchocerciasis is endemic, infants are often breastfed up to the age of 2 years, suggesting that some women are likely to be lactating during such periodic MDA programs. Quantitative analyses of non-clinical and clinical data using non-compartmental analysis and population based pharmacokinetic (popPK) modeling as well as physiologically based pharmacokinetic modeling (PBPK) were performed to determine the amount of moxidectin excreted in breast milk and subsequent exposures in the infant. The results of the analyses were similar. Concentrations of moxidectin in breast milk followed a similar pattern to those in plasma, with maximum concentrations occurring approximately 4 hours after dosing followed by a rapid decline in both breast milk and plasma. As early as two days after dosing, concentrations of moxidectin in breast milk were below the threshold for acceptable daily intake levels established by the European Medicines Agency (EMA) and FDA for secondary exposures from veterinary use, and below the WHO recommended relative infant dose (RID) safety threshold. The analyses were conducted to support prescribers and policy makers on dosing recommendations for moxidectin in lactation.<\/jats:p>","DOI":"10.1371\/journal.pntd.0012351","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T17:54:55Z","timestamp":1722880495000},"page":"e0012351","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["The use of quantitative clinical pharmacology approaches to support moxidectin dosing recommendations in lactation"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4051-6487","authenticated-orcid":true,"given":"Nolan D.","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danelle","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally A.","family":"Kinrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig R.","family":"Rayner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wesche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashyap","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rowland-Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"pntd.0012351.ref001","volume-title":"Onchocerciasis Fact Sheet","author":"World Health Organisation (WHO)","year":"2019"},{"key":"pntd.0012351.ref002","unstructured":"Stromectol FDA approved product label: Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050742slbl.pdf"},{"key":"pntd.0012351.ref003","first-page":"311","volume-title":"Use of Ivermectin in Humans","author":"BM Greene","year":"1989"},{"key":"pntd.0012351.ref004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2183\/pjab.87.13","article-title":"Review: Ivermectin \u201cWonder drug\u201d from Japan: the human use perspective","volume":"87","author":"A Crump","year":"2011","journal-title":"Proc. Jpn. Acad. Ser"},{"key":"pntd.0012351.ref005","unstructured":"WHO 2006: Preventive chemotherapy in human helminthiasis: Available from: https:\/\/www.afro.who.int\/sites\/default\/files\/2017-06\/preventive-chemotherapy-in-human-helminthiasis.pdf"},{"key":"pntd.0012351.ref006","first-page":"272","article-title":"Research for new drugs for elimination of onchocerciasis in Africa.","volume":"6","author":"AC Kuesel","year":"2016","journal-title":"International Journal for Parasitology: Drugs and Drug Resistance"},{"key":"pntd.0012351.ref007","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40249-019-0567-z","article-title":"Reaching the last mile: main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa","volume":"8","author":"G Gebrezgabiher","year":"2019","journal-title":"Infectious Diseases of Poverty"},{"key":"pntd.0012351.ref008","unstructured":"Moxidectin FDA approved product label (2021). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/210867s003lbl.pdf"},{"issue":"11","key":"pntd.0012351.ref009","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14787210.2020.1792772","article-title":"Moxidectin: an oral treatment for human onchocerciasis","volume":"18","author":"P Milton","year":"2020","journal-title":"Expert Review of anti-infective therapy"},{"issue":"3","key":"pntd.0012351.ref010","first-page":"e000100005","article-title":"Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection","volume":"16","author":"B Tan","year":"2022","journal-title":"Trop Dis"},{"key":"pntd.0012351.ref011","unstructured":"Centers for Disease Control and Prevention: Neglected Tropical Diseases. Available from: https:\/\/www.cdc.gov\/globalhealth\/ntd\/features\/oncho_launch.html"},{"key":"pntd.0012351.ref012","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2049-9957-3-21","article-title":"Global burden, distribution, and interventions for diseases of poverty","volume":"3","author":"ZA Bhutta","year":"2014","journal-title":"Infectious Diseases of Poverty"},{"key":"pntd.0012351.ref013","unstructured":"Unicef Report 2018: Breastfeeding: A mother\u2019s gift, for every child: Available from: https:\/\/data.unicef.org\/resources\/breastfeeding-a-mothers-gift-for-every-child\/"},{"issue":"12","key":"pntd.0012351.ref014","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10121588","article-title":"Treatment of pregnant women with ivermectin during mass drug distribution: Time to investigate its safety and potential benefits","volume":"10","author":"AC Erber","year":"2021","journal-title":"Pathogens"},{"issue":"2","key":"pntd.0012351.ref015","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/bcp.15148","article-title":"Twice neglected? Neglected diseases in neglected populations","volume":"88","author":"ED Weld","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"pntd.0012351.ref016","unstructured":"Stromectol (ivermectin tablet USP 3 mg) Product Monograph including patient medication information, Section 7.1.2, Merck Canada Inc. October 21, 2021: Available from: https:\/\/www.merck.ca\/en\/wp-content\/uploads\/sites\/20\/2021\/04\/STROMECTOL-PM_E.pdf"},{"issue":"4","key":"pntd.0012351.ref017","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF00265962","article-title":"Ivermectin levels in human breastmilk","volume":"45","author":"JE Ogbuokiri","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"pntd.0012351.ref018","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF00195923","article-title":"Ozumba BC, Okonkwo PO. Ivermectin levels in human breastmilk","volume":"46","author":"JE Ogbuokiri","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"pntd.0012351.ref019","doi-asserted-by":"crossref","first-page":"105249","DOI":"10.1016\/j.actatropica.2019.105249","article-title":"Ivermectin concentrations in breastmilk of a woman with Strongyloides stercoralis and human T-lymphocytic virus-I co-infection","volume":"202","author":"P Rodari","year":"2020","journal-title":"Acta Tropica"},{"issue":"11","key":"pntd.0012351.ref020","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.1128\/AAC.00311-11","article-title":"Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women","volume":"55","author":"JM Korth-Bradley","year":"2011","journal-title":"Antimicrob agents and Chemo"},{"key":"pntd.0012351.ref021","unstructured":"Moxidectin FDA approved product label (2018). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210867lbl.pdf"},{"key":"pntd.0012351.ref022","unstructured":"Centre for Drug Evaluation and Research: Clinical pharmacology and Biopharmaceutics review(s): Application Number 210867Orig1s000: Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210867Orig1s000ClinPharmR.pdf"},{"key":"pntd.0012351.ref023","unstructured":"EMEA\/MRL\/777\/01-Final, February 2001. Committee for Veterinary Medicinal Products: Moxidectin (Modification of the ADI and extension to bovine milk) Summary Report (3). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/mrl-report\/moxidectin-modification-adi-extension-bovine-milk-summary-report-3-committee-veterinary-medicinal_en.pdf"},{"key":"pntd.0012351.ref024","unstructured":"Code of Federal Regulations Title 21 (as of Mar 29, 2022): Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=556.426"},{"issue":"1","key":"pntd.0012351.ref025","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/cpt.2912","article-title":"Physiologically Based Pharmacokinetic Modeling to Determine the Impact of CYP2B6 Genotype on Efavirenz Exposure in Children, Mothers and Breastfeeding Infants","volume":"114","author":"X Pan","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"pntd.0012351.ref026","first-page":"S106","article-title":"Informing a Comprehensive Risk Assessment of Infant Drug Exposure From Human Milk: Application of a Physiologically Based Pharmacokinetic Lactation Model for Sotalol","volume":"63","author":"MA Pressly","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"pntd.0012351.ref027","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"H Jones","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"pntd.0012351.ref028","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","article-title":"Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children","volume":"45","author":"TN Johnson","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"38","key":"pntd.0012351.ref029","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.2174\/1381612823666171009143840","article-title":"PBPK in Preterm and Term Neonates: A Review","volume":"23","author":"R Michelet","year":"2017","journal-title":"Curr Pharm Des"},{"issue":"7","key":"pntd.0012351.ref030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/psp4.12306","article-title":"PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants.","volume":"7","author":"C Emoto","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"pntd.0012351.ref031","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/bcp.14528","article-title":"Use of a physiologically based pharmacokinetic-pharmacodynamic model for initial dose prediction and escalation during a paediatric clinical trial","volume":"87","author":"TN Johnson","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"pntd.0012351.ref032","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/cts.12583","article-title":"Evaluation of the Cardiac Safety of Long-Acting Endectocide Moxidectin in a Randomized Concentration-QT Study","volume":"11","author":"SA Kinrade","year":"2018","journal-title":"Clin Transl Sci."},{"issue":"7","key":"pntd.0012351.ref033","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-014-0140-7","article-title":"A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data","volume":"53","author":"F Salem","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"pntd.0012351.ref034","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1124\/dmd.115.068643","article-title":"How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach","volume":"44","author":"TN Johnson","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"pntd.0012351.ref035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-019-3075-5","article-title":"An in vitro toolbox to accelerate anti-malarial drug discovery and development","volume":"19","author":"SA Charman","year":"2020","journal-title":"Malar J"},{"key":"pntd.0012351.ref036","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejps.2013.09.006","article-title":"Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS\/BDDCS Class II drug nifedipine","volume":"57","author":"N Patel","year":"2014","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"pntd.0012351.ref037","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cbi.2009.02.009","article-title":"In vitro and in vivo interaction of moxidectin with BCRP\/ABCG2","volume":"180","author":"M Perez","year":"2009","journal-title":"Chem Biol Interact"},{"key":"pntd.0012351.ref038","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/BF01059554","article-title":"Prediction of the volumes of distribution of basic drugs in humans based on data from animals","volume":"12","author":"HM Sawada Y","year":"1984","journal-title":"J Pharmacokinet Biopharm"},{"issue":"6","key":"pntd.0012351.ref039","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"T Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"key":"pntd.0012351.ref040","unstructured":"Drugs and Lactation Databsed (LactMed): Available from; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501922\/"},{"issue":"5","key":"pntd.0012351.ref041","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.3390\/nu12051404","article-title":"The comparison of nutritional value of human milk with other mammals milk","volume":"12","author":"R Pietrzak-Fiecko","year":"2020","journal-title":"Nutrients"},{"issue":"1","key":"pntd.0012351.ref042","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/cpt.377","article-title":"Modeling drug passage into human milk","volume":"100","author":"PO Anderson","year":"2016","journal-title":"Clinical Pharmacol. Ther"},{"issue":"6","key":"pntd.0012351.ref043","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/cpt.676","article-title":"Evaluation of the safety of drugs and biological products used during lactation: Workshop summary","volume":"101","author":"J Wang","year":"2017","journal-title":"Clin. Pharmacol. Ther"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0012351","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T17:56:08Z","timestamp":1723744568000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012351"}},"subtitle":[],"editor":[{"given":"Roger K.","family":"Prichard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0012351","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0012351","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]}}}